Pfizer Lipitor Patents Valid, Infringed By Ranbaxy, Court Says
This article was originally published in The Pink Sheet Daily
Executive Summary
If affirmed on appeal, the ruling means that ANDA first filer Ranbaxy would be unable to launch atorvastatin generics before 2011.